Neuroinflammation in COVID-19 and Depression

Center for Addiction and Mental Health (CAMH)

Status

Completed

Conditions

Major Depressive Episode

Covid19

Treatments

Other: [11C]SL25.1188 PET scan

Other: [18F]FEPPA PET scan

Study type

Observational

Funder types

Other

Identifiers

NCT04854785

177/2020

Details and patient eligibility

About

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

Full description

Participants will undergo two positron emission tomography (PET) scans: one [18F]FEPPA scan (for translocator protein (TSPO)) and one [11C]SL25.1188 scan (for monoamine oxidase B (MAO-B)) - as well as one magnetic resonance imaging (MRI) scan.

The primary hypotheses are:

TSPO total distribution volume (TSPO VT) and MAO-B total distribution volume (MAO-B VT) are greater in the prefrontal cortex (PFC), anterior cingulate cortex (ACC), and hippocampus in COVID-19 with new onset, persistent major depressive episode (MDE) with or without other neuropsychiatric symptoms after recovery from mild respiratory symptoms (DNP-mild).
TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new onset, persistent MDE with or without other persistent neuropsychiatric symptoms after recovery from moderate respiratory symptoms (DNP-moderate).

Exploratory hypotheses are:

Greater TSPO VT and MAO-B VT in the PFC, ACC, and hippocampus will be positively associated with severity of MDE symptoms and poorer performance on cognitive tasks.
TSPO VT and MAO-B VT will be positively correlated in the PFC, ACC and hippocampus in COVID-DNP.

Enrollment

77 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age 18 to 80
Diagnosis of COVID-19
Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen.
Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks
New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV)
High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing

Exclusion criteria

Lifetime history of an autoimmune disease
Lifetime history of a neurological disease, excluding migraine
Lifetime diagnosis of Antisocial or Borderline Personality disorder
Lifetime history of psychotic symptoms prior to COVID-19
Lifetime diagnosis of Substance of Alcohol Use Disorder
Use of street drugs, including marijuana, in the past two months
Presence of cigarette smoking in the past two months
Positive urine drug or cotinine screen at any timepoint during the study
Currently pregnant
Currently breastfeeding
Use of aspirin or ibuprofen within the past 2 weeks
Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks
Use of herbal remedies in the past month
Presence of metal implant, object or electrical devices that are contraindicated for MRI
Current disorders of coagulation, blood or ongoing use of anticoagulant medication
Claustrophobia
Weight over 400lbs and height over 7ft
History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study
Current participation in another research study